Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409236 · ClinicalTrials.gov registry record · Phase 3
Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking
A Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 427
- Enrollment target
- 1
- Study location
NCT04409236: Active Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, sponsored by Fred Hutchinson Cancer Center.
NCT04409236 is a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 427 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04409236, a Phase 3 study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid System Neoplasm, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 427 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking. Both apps provide tools to cope with urges to smoke, step-by-step guides for quitting smoking, help in planning for quitting and staying tobacco-free, and scientifically-based recommendations for how to select medications that aid in smoking cessation.
Primary Outcome
The primary endpoint is 30-day point prevalence abstinence for cigarette smoking at 12 months post-randomization. At 12 months, smoking abstinence is assessed by asking participants: "When was the last time you smoked, or even tried, a cigarette?" Response choices are "Earlier today", "24 hours ago", "2-7 days ago", "8-30 days ago", and "Over 30 days ago". Participants reporting no cigarette consumption in the past 30 days are considered abstinent for the 30-day outcome. Missing outcome data are
Conditions Studied
Interventions
- OTHER Survey Administration
- BEHAVIORAL QuitGuide
- BEHAVIORAL Quit2Heal
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2026-09-11 |
| Phase | Phase 3 |
What the registry record for NCT04409236 still lists
NCT04409236 is an interventional study that assigns participants to a tested intervention. The registered 427 participants enrollment target is mid-sized for trials with a published cap, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.
NCT04409236 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04409236 about?
NCT04409236 is a clinical study titled "Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking". This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking. Both apps provide tools to cope with urges to smoke, step-by-step guides for quitting smoking, help in planning for quitting and staying tobacco-fr...
What is the current status of trial NCT04409236?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 427 participants. The study started on 2021-07-19. Estimated completion is 2026-09-11.
What conditions does trial NCT04409236 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm.
What interventions are being tested in trial NCT04409236?
The interventions under investigation include: Survey Administration (OTHER), QuitGuide (BEHAVIORAL), Quit2Heal (BEHAVIORAL).
Who is sponsoring clinical trial NCT04409236?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04409236 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04409236's enrollment target sits among peer trials
427 33rd of 176 higher than 144 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
RECRUITING · Phase 3
-
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
RECRUITING · Phase 3
-
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
RECRUITING · Phase 3
-
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
RECRUITING · Phase 3
-
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RECRUITING · Phase 3
-
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI